Company: TXG
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001770787-25-000051
Chunk: 2

Company: 10x Genomics, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
Item 1.    Financial Statements.

10x Genomics, Inc.

Condensed Consolidated Balance Sheets

 (In thousands)

June 30,2025December 31,2024(Unaudited)(Note 1)AssetsCurrent assets:Cash and cash equivalents$397,712 $344,067 Marketable securities49,549 49,335 Accounts receivable, net49,977 87,862 Other receivables69,090 606 Inventory68,968 83,107 Prepaid expenses and other current assets20,365 19,410 Total current assets655,661 584,387 Property and equipment, net239,710 252,648 Operating lease right-of-use assets62,700 57,290 Goodwill4,511 4,511 Intangible assets, net14,714 15,671 Other noncurrent assets2,674 4,129 Total assets$979,970 $918,636 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$15,938 $12,909 Accrued compensation and related benefits26,102 33,615 Accrued expenses and other current liabilities39,063 41,165 Deferred revenue21,449 20,658 Operating lease liabilities9,669 9,286 Total current liabilities112,221 117,633 Operating lease liabilities, noncurrent77,075 73,327 Deferred revenue, noncurrent11,270 12,513 Other noncurrent liabilities6,125 5,029 Total liabilities206,691 208,502 Commitments and contingencies (Note 5)Stockholders’ equity:Preferred stock— — Common stock2 2 Additional paid-in capital2,239,924 2,177,672 Accumulated deficit(1,466,867)(1,467,047)Accumulated other comprehensive income (loss)220 (493)Total stockholders’ equity773,279 710,134 Total liabilities and stockholders’ equity$979,970 $918,636  

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

Table of Contents

10x Genomics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

Three Months EndedJune 30,Six Months EndedJune 30